Merck KGaA has entered into a licensing agreement with Cyclica Inc. for the use of Ligand Express, a cloud-based in silico proteome screening platform. Ligand Express is a structure-based and artificial intelligence (AI) augmented platform that is being used to uncover novel targets that are modeled to interact with a small molecule. The one-year agreement will enable Merck KGaA to quickly and efficiently elucidate mechanisms of action, evaluate safety profiles and explore additional application...